Global Macular Edema Market Research Report 2014-2018

According to the Report “Global Macular Edema Market 2014-2018”, Macular edema results from fluid accumulation in the macular region of the retina. Macular edema arises from various etiologies such as diabetes, AMD, and RVO. Macular edema disrupts the central vision due to swelling of the macula. Currently, the treatment plan involves the use of surgical and laser therapies as well as drugs such as anti-VEGF therapies and NSAIDs. Surgery and laser therapy are intended to prevent further damage to vision. However, anti-VEGF therapies have been reported to improve the vision loss associated with macular edema.

Analysts forecast the Global Macular Edema market will grow at a CAGR of 9.1 percent over the period 2014-2018.

Purchase a Copy of the Report Directly @

The Report recognizes the following companies as the key players in the Global Macular Edema Market : Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Alimera Sciences Inc., Allergan Inc., Ampio Pharmaceuticals Inc., iCo Therapeutics Inc.,Pfizer Inc., Santen Pharmaceutical Co. Ltd.

NICE issues and updates technology appraisals and clinical guidelines to recommend appropriate and effective treatments for different diseases. It plays a role in increasing drug sales. In January 2013, NICE recommended Lucentis for the treatment of DME. This recommendation superseded the November 2011 guidance, which concluded that recommending Lucentis was not effective utilization of NHS resources. Lucentis has also been recommended for the treatment of vision impairment as a result of macular edema associated with RVO.

Inquire Before buying the Report @

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Macular Edema market for the period 2013-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat macular edema associated with distinct etiologies.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Macular Edema market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Global Macular Edema Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Macular Edema market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, the Global Macular Edema market is driven by several factors, of which the increase in the patient population is one of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD, inflammatory conditions such as uveitis, and RVO cause macular edema. The increase in the incidence and prevalence of ophthalmological conditions such as AMD and DR is expected to increase the patient population with macular edema during the forecast period.

Further, the report states that although the Global Macular Edema market has several drivers, the growth of the market is curtailed by some serious challenges. One of the main challenges is increased use of off-label drugs. Use of off-label drugs increases the market competition for approved branded drugs. Some of the off-label drugs for the treatment of macular edema are bevacizumab, topical NSAIDs, and drugs such as acetazolamide.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

Other Prominent Vendors

  • Alcon Inc.
  • Alimera Sciences Inc.
  • Allergan Inc.
  • Ampio Pharmaceuticals Inc.
  • iCo Therapeutics Inc.
  • Pfizer Inc.
  • Santen Pharmaceutical Co. Ltd.

Key Market Driver

  • Increase in Patient Population

Key Market Challenge

  • Increasing Use of Off-label Drugs

Key Market Trend

  • Increasing Recommendations by NICE

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?